|
1
|
Fidler IJ: The pathogenesis of cancer
metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003.
|
|
2
|
Nguyen DX, Bos PD and Massague J:
Metastasis: from dissemination to organ-specific colonization. Nat
Rev Cancer. 9:274–284. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bos PD, Zhang XH-F, Nadal C, et al: Genes
that mediate breast cancer metastasis to the brain. Nature.
459:1005–1009. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jorissen RN, Walker F, Pouliot N, Garrett
TPJ, Ward CW and Burgess AW: Epidermal growth factor receptor:
mechanisms of activation and signaling. Exp Cell Res. 284:31–53.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hynes NE and Lane HA: ERBB receptors and
cancer: the complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu X and Kang Y: Epidermal growth factor
signaling and bone metastasis. Br J Cancer. 102:457–461. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yagi H, Yotsumoto F and Miyamoto S:
Heparin-binding epidermal growth factor-like growth factor promotes
transcoelomic metastasis in ovarian cancer through
epithelial-mesenchymal transition. Mol Cancer Ther. 7:3441–3451.
2008. View Article : Google Scholar
|
|
8
|
Goishi K, Higashiyama S, Klagsbrun M, et
al: Phorbol ester induces the rapid processing of cell surface
heparin-binding EGF-like growth factor: conversion from juxtacrine
to paracrine growth factor activity. Mol Biol Cell. 6:967–980.
1995. View Article : Google Scholar
|
|
9
|
Higashiyama S, Abraham JA, Miller J,
Fiddes JC and Klagsbrun M: A heparin-binding growth factor secreted
by macrophage-like cells that is related to EGF. Science.
251:936–939. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Higashiyama S, Abraham JA and Klagsbrun M:
Heparin-binding EGF-like growth factor stimulation of smooth muscle
cell migration: dependence on interactions with cell surface
heparin sulfate. J Cell Biol. 122:933–940. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ongusaha PP, Kwak JC, Zwible AJ, et al:
HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer
Res. 64:5283–5290. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miyamoto S, Hirata M, Yamazaki A, et al:
Heparin-binding EGF-like growth factor is a promising target for
ovarian cancer therapy. Cancer Res. 64:5720–5727. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Freeman MR, Yoo JJ, Raab G, et al:
Heparin-binding EGF-like growth factor is an autocrine growth
factor for human urothelial cells and is synthesized by epithelial
and smooth muscle cells in the human bladder. J Clin Invest.
99:1028–1036. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Weaver MA: Invadopodia: specialized cell
structures of cancer invasion. Clin Exp Metastasis. 23:97–105.
2006. View Article : Google Scholar
|
|
15
|
Nakagawa M, Nabeshima K, Asano S, et al:
Up-regulated expression of ADAM17 in gastrointestinal stromal
tumors: coexpression with EGFR and EGFR ligands. Cancer Sci.
100:654–662. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cohen S: Origins of growth factors: NGF
and EGF. Ann NY Acad Sci. 1038:98–102. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iwasaki S, Aoyagi H and Yoshizawa H:
Immunohistochemical detection of epidermal growth factor and
epidermal growth factor receptor in the lingual mucosa of rats
during the morphogenesis of fili form papileae. Acta Histochem.
109:37–44. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iwamoto R and Mekada E: Heparin-binding
EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth
Factor Rev. 11:335–344. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Izumi Y, Hirata M, Hasuwa H, et al: A
metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKC-delta
are involved in TPA-induced ectodomain shedding of
membrane-anchored heparin-binding EGF-like growth factor. EMBO J.
17:7260–7272. 1998. View Article : Google Scholar
|
|
20
|
Suzuki M, Raab G, Moses MA, Fernandez CA
and Klagsbrun M: Matrix metalloproteinase-3 releases active
heparin-binding EGF-like growth factor by cleavage at a specific
juxtamembrane site. J Biol Chem. 272:31730–31737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fischer OM, Hart S, Gschwind A and Ullrich
A: EGFR signal transactivation in cancer cells. Biochem Soc Trans.
31:1203–1208. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miyamoto S, Yagi H, Yotsumoto F,
Kawarabayashi T and Mekada E: Heparin-binding epidermal growth
factor-like growth factor as a novel targeting molecule for cancer
therapy. Cancer Sci. 97:341–347. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Razandi M, Pedram A, Park ST and Levin ER:
Proximal events in signaling by plasma membrane estrogen receptors.
J Biol Chem. 278:2701–2712. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gooz M, Gooz P, Luttrell LM and Raymond
JR: 5-HT2A receptor induces ERK phosphorylation and proliferation
through ADAM-17 tumor necrosis factor-alpha-converting enzyme
(TACE) activation and heparin-bond epidermal growth factor-like
grow factor (HB-EGF) shedding in mesangial cells. J Biol Chem.
281:21004–21012. 2006. View Article : Google Scholar
|
|
25
|
Horiuchi K, Le Gall S, Schulte M, et al:
Substrate selectivity of epidermal growth factor-receptor ligand
sheddases and their regulation by phorbol esters and calcium
influx. Mol Biol Cell. 18:176–188. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sahin U, Weskamp G, Kelly K, et al:
Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six
EGFR ligands. J Cell Biol. 164:769–779. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zheng X, Jiang F, Katakowski M, Zhan ZG,
Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant
phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther.
8:1045–1054. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu PCC, Liu X, Li Y, et al:
Identification of ADAM10 as a major source of HER2 ectodomain
sheddase activity in HER2 overexpressing breast cancer cell. Cancer
Biol Ther. 5:657–664. 2006.PubMed/NCBI
|
|
29
|
Wikstland CJ, Reist CJ, Archer GE,
Zalutsky MR and Bigner DD: The class III variant of the epidermal
growth factor receptor (EGFRvIII): characterization and utilization
as an immunotherapeutic target. J Neurovirol. 4:148–158. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsujioka H, Yotsumoto F, Hikita S, Ueda T,
Kuroki M and Miyamoto S: Targeting the heparin-binding epidermal
growth factor-like growth factor in ovarian cancer therapy. Curr
Opin Obstet Gynecol. 23:24–30. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang F, Sloss C, Zhang X, Lee SW and
Cusack JC: Membrane-bound heparin-binding epidermal growth
factor-like growth factor regulates E-cadherin expression in
pancreatic carcinoma cells. Cancer Res. 67:8486–8493. 2007.
View Article : Google Scholar
|
